This study wants to see how a special drug, called sacituzumab govitecan (SG), works for people with endometrial cancer. Endometrial cancer is a type of cancer that starts in the lining of the uterus. The study compares SG with the usual treatments doctors choose, called Treatment of Physician's Choice (TPC). Participants should have already tried chemotherapy with a drug containing platinum and a kind of treatment called immunotherapy. The main goals are to check how long people live without their cancer getting worse (progression-free survival) and overall survival.

To join, participants should have endometrial cancer that has come back or is still there after treatment. They must have had up to three treatments before and be able to have certain medicines like doxorubicin or paclitaxel. They need to have cancer that can be seen on scans and good organ function. Some people can't join, like those with certain other types of cancer, serious infections, or if they are pregnant.

• The study will compare SG with usual doctor-chosen treatments.
• Must have had up to three treatments before joining.
• Cannot join if you have certain other health issues.